Macrotroponin Complex as a Cause for Cardiac Troponin Increase after COVID-19 Vaccination and Infection

Anda Bularga, Ellen Oskoui, Takeshi Fujisawa, Sara Jenks, Rachel Sutherland, Fred S. Apple, Ola Hammarsten, and Nicholas L. Mills

DESCRIPTION OF CASES

Patient 1 was a 28-year-old Caucasian woman who presented with a 4-day history of chest pain to the same day emergency care unit at the Western General Hospital, Edinburgh, Scotland. The patient had received a second dose of the mRNA-1273 (Moderna) vaccine for COVID-19 five days previously. After vaccination, she felt unwell with fever and dry cough. Shortly after, she developed chest pain. The patient had no background medical history and her clinical examination was unremarkable.

Patient 2 was a 29-year-old Caucasian man who presented with chest pain to the Sahlgrenska University Hospital, Gothenburg, Sweden. The patient had received a second dose of the mRNA-1273 (Moderna) vaccine 3 weeks prior to admission. He described a similar episode of chest discomfort a few days after vaccination. The patient had a history of asthma but was not receiving regular medication. His clinical examination was normal.

Patient 3 was a 19-year-old Caucasian man who had COVID-19 confirmed using a reverse transcription-PCR test. He experienced mild breathlessness and headache and was generally unwell. Six weeks following confirmed COVID-19 infection, he developed chest pain, which prompted admission to the Sahlgrenska University Hospital, Gothenburg, Sweden. The patient had a history of asthma. The clinical examination was normal.

INVESTIGATIONS

High-sensitivity cardiac troponin (hs-cTn) testing was performed at presentation, repeated 3 or 6 h later, and on follow-up. hs-cTnI was measured on Abbott ARCHITECT STAT (i2000) or Abbott Alinity (ci), and hs-cTnT was measured on the Roche Diagnostics Elecsys (Cobas e801) platforms. The limit of detection for hs-cTnI ranges from 1.2 to 1.9 ng/L, and sex-specific 99th percentiles are 16 ng/L (females) and 34 ng/L (males). The limit of detection for hs-cTnT is 3 ng/L, and sex-specific 99th percentiles are 9 ng/L (females) and 16 ng/L (males).

In all 3 patients, hs-cTnI concentrations were increased at 31 ng/L, 750 ng/L, and 280 000 ng/L on presentation, but the electrocardiogram was normal, with no ST-segment or T-wave abnormalities (Table 1). Admission laboratory investigations identified normal hematologist for all patients. Serial measures of hs-cTnI concentrations were increased at 31 ng/L, 750 ng/L, and 280 000 ng/L on presentation, but the electrocardiogram was normal, with no ST-segment or T-wave abnormalities (Table 1). Admission laboratory investigations identified normal hematologist for all patients.

QUESTIONS TO CONSIDER

1. What are the causes of cTn assay interference?
2. What is the process of testing for immunoglobulin-bound cTn complexes or macrotroponins when assay interference is suspected?
3. When should the possibility of assay interference be considered in clinical practice?
| Table 1. Clinical characteristics of patients with cardiac troponin assay interference in the context of COVID-19 infection or vaccination. |
|---------------------------------------------------------------|
| **Patient** | **1** | **2** | **3** |
| Age, years | 29 | 28 | 19 |
| Sex | Female | Male | Male |
| Prior cardiac history | None | None | None |
| COVID-19 infection | No | No | Yes |
| Immunization against COVID-19 | | | |
| Vaccine type | mRNA-1273 (Moderna) | mRNA-1273 (Moderna) | — |
| Vaccine dose | Second dose | Second dose | — |
| Symptoms | | | |
| Primary presenting symptom | Chest pain | Chest pain | Chest pain |
| Other symptoms | Cough | Palpitations | Shortness of breath |
| Laboratory information | | | |
| hs-cTnI assay platform | Abbott ARCHITECT STAT (i2000) | Abbott Alinity (ci) | Abbott Alinity (ci) |
| hs-cTnT assay platform | Roche Elecsys (Cobas e801) | Roche Elecsys (Cobas e801) | Roche Elecsys (Cobas e801) |
| Laboratory investigation results | | | |
| hs-cTnI, ng/L (presentation) | 31 | 750 | 280 000 |
| hs-cTnT, ng/L (presentation) | 4 | 33 | 11 |
| hs-cTnI, ng/L (serial) | 37 | 770 | 180 000 |
| hs-cTnT, ng/L (serial) | 5 | — | 6 |
| hs-cTnI, ng/L (follow-up) | 48 | 696 | 93 000 |
| hs-cTnT, ng/L (follow-up) | 5 | — | 10 |
| Macrotroponin complex analysis | | | |
| Macrotroponin complex | IgG to hs-cTnI and to hs-cTnT | IgG and IgM to hs-cTnI | |
| hs-cTnI concentration (ng/L) prior to immune complex removal* | 58 | 860 | 180 000 |
| hs-cTnI concentration (ng/L) after immune complex removal* | 10 | 5 | 13 |
| hs-cTnI recovery, % | 16 | 3 | <1 |
| hs-cTnT concentration (ng/L) prior to immune complex removal | <3 | 33 | 11 |
| hs-cTnT concentration (ng/L) after immune complex removal | <3 | 6 | 11 |
| hs-cTnT recovery, % | — | 3 | — |
| Macrotroponin complex molecular weight, kDa | 200 | 200 | 500 |
| Suspected clinical diagnosis | Vaccine-associated myocarditis | Vaccine-associated myocarditis | COVID-19 myocarditis |
| Continued | | | |
and findings suggestive of a restrictive left ventricular filling pattern. Patients 2 and 3 underwent cardiac magnetic resonance imaging, which was normal in patient 3, but demonstrated reduced ejection fraction at 54% in patient 2. As a result, this patient had an endomyocardial biopsy, which identified enlarged myocytes consistent with a restrictive cardiomyopathy and ruled out myocarditis.

### CARDIAC TROPONIN IMMUNOASSAY INTERFERENCE

Stored surplus sample was tested using a hs-cTnT assay, which returned normal values of 4 ng/L and 8 ng/L for patients 1 and 3, respectively. Patient 2 had an increased hs-cTnT concentration of 33 ng/L, discordant with the hs-cTnI value of 860 ng/L (Table 1).

To test for immunoglobulin-bound cTn complexes (macrotrponins) or interference due to heterophile antibodies, IgG, IgA, or IgM were removed using affinity chromatography by treating plasma with a protein G column (HiTrap, Protein G HP, GE Healthcare) (1), anti-IgA (CaptureSelect® IgA affinity matrix, Thermo Scientific), or anti-IgM (Poros®CaptureSelect® IgM affinity matrix, Thermo Scientific) resins in a spin column format using Bio-Rad minicolumn. Macrotroponin is retained on the affinity resin resulting in a lower recovery of cTn. In acute myocardial infarction, recovery is 100% (2). The native molecular weight of cTnI was analyzed using 18% to 42% sucrose gradient ultracentrifugation. Simultaneous centrifugation of standard marker proteins allows estimation of sedimentation coefficients to determine the molecular weight of the protein of interest (3). Free cTnI has a molecular weight of around 20 kDa whereas the molecular weight of macrotroponin complex is around 200 kDa allowing analysis of both the free and the bound fraction (2).

For patient 1, hs-cTnI concentrations decreased from 58 ng/L to 10 ng/L, with a recovery of 16% following removal of IgG. In patient 2, an IgG macrotroponin complex affecting both hs-cTnI and hs-cTnT assays was detected with hs-cTnI concentrations, decreasing from 860 ng/L to 5 ng/L, and hs-cTnT concentrations, decreasing from 33 ng/L to 6 ng/L, with a recovery of 3% in both cases. For patient 3, a combined IgG and IgM macrotroponin complex affecting the hs-cTnI assay was identified with a decrease in hs-cTnI from 180 000 ng/L to 13 ng/L and a recovery of <1%. In patients 1 and 3, hs-cTnT concentrations were too low to be analyzed by ultracentrifugation.

### FOLLOW-UP

Patient 1 returned for follow-up 6 weeks after admission. Her symptoms had subsided, and on further questioning, she described recurrent chest pains that were associated with movement. The pain resolved with simple analgesia. As previously, hs-cTnI concentrations were increased at 48 ng/L, but hs-cTnT concentrations were within the reference interval at 5 ng/L (Table 1). Patient 2 returned for ongoing investigations, and hs-cTnI remained increased on serial testing at 696 ng/L, although his symptoms had resolved. Patient 3 was followed up in the ambulatory clinic and reported no further complaints of chest pain or breathlessness, but hs-cTnI concentrations remained increased at 93 000 ng/L.

### DISCUSSION

While multiple cases of myocarditis have been reported following COVID-19 infection and associated with mRNA vaccination in young adults (4), the cellular
and immune mechanisms responsible for these observations are unclear. Although no cases of myocarditis were observed in the randomized, placebo-controlled trials of COVID-19 vaccines, this condition is uncommon, and it is not surprising that safety concerns only appeared during postmarket authorization surveillance. Indeed, myocarditis has been reported as an adverse event with other vaccines, for example, after live vaccinia virus vaccine for smallpox (5).

Establishing the diagnosis of myocarditis may be challenging. In practice, this is based on the detection of an increased cTn, with or without evidence of new impairment of ventricular function, and by the exclusion of other causes of myocardial injury (6). In our case studies, the temporal relationship between the onset of chest pain and mRNA-1273 vaccine or recent COVID-19 infection raised clinical suspicion of myocarditis. However, in all patients, the electrocardiogram was unremarkable, and the findings on imaging with echocardiography and cardiac magnetic resonance imaging did not support the diagnosis. While the sensitivity of echocardiography is limited, one would have expected to identify myocardial edema or patchy late gadolinium enhancement on magnetic resonance imaging or lymphocytic infiltration and active myocyte necrosis on cardiac biopsy if cTn increases were due to acute myocarditis. Furthermore, cTn concentrations were unchanged on serial measurement whereas one would expect a rise and/or fall in concentrations consistent with the acute nature of this condition. Given these findings in otherwise healthy young adults, hs-cTnI immunoassay interference was suspected. Measurement of hs-cTnT demonstrated discordance between hs-cTnI and hs-cTnT concentrations.

False-positive cTn increases due to immunoassay interference have been described in many conditions but not in the context of COVID-19 infection or following vaccination. It is estimated that analytical false positives for cTn occur in approximately 1 in 1000 patients (7). Multiple causes for assay interference have been identified, such as heterophilic antibodies, rheumatoid factor, macrotroponin complex, and human antimicrobial antibodies in response to monoclonal antibodies used in production of therapeutic agents or vaccination (7). In addition, increases in hs-cTnT concentrations can be associated with reexpression of cTn in skeletal muscle in the absence of cardiac involvement (8). Clinicians should be aware of the possibility of immunoassay interference, particularly if there is discordance between cTn concentrations and the clinical presentation or other investigation results.

In view of the temporal association between COVID-19 vaccine administration or infection and the detection of immunoassay interference, we hypothesize that increased hs-cTn concentrations could be due to interference caused by the immune response to mRNA-1273 vaccination or COVID-19 infection. The plausibility of our hypothesis is supported directly by the identification of macrotroponin complex in all 3 patients and indirectly by a similar observation of interference using an immunoassay for HIV in 2 patients with COVID-19 infection (9). The COVID-19 mRNA vaccines elicit a strong immune response with increased plasma IgA, IgM, and IgG activity and monoclonal antibodies against SARS-CoV-2 spike protein and the receptor-binding domain (10). Immunoglobulins can bind multiple proteins in circulation with the resulting complexes cleared in the lymphatic system. Clearance of the bound protein is delayed resulting in increased plasma concentrations. The phenomenon is well known for prolactin, called macroprolactin, but also occurs for cTn, especially hs-cTnI, possibly because it is more immunogenic compared to hs-cTnT, at least in animal models (7). The hs-cTnI antibodies most often form long-lived antibody complexes resulting in false-positive results (3). cTn increases due to macroprotonin complex do not increase cardiovascular risk; however, they may result in misdiagnosis, overinvestigation, and a risk of harm from invasive procedures, such as cardiac biopsy.

When assessing patients with suspected acute and long-term cardiac complications following COVID-19 infection or vaccination, clinicians should be aware of the potential for false-positive cTn increases due to assay interference. This may have important implications on downstream testing and patient well-being.

**Author Contributions:** All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4
requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

A. Bularga and N.L. Mills drafted the report. O. Hammarsten performed additional analysis. A. Bularga, E. Oskoui, T. Fujisawa, S. Jenks, R. Sutherland, F.S. Apple, O. Hammarsten, and N.L. Mills revised the manuscript for important intellectual content. All authors provided their final approval of the version to be published. All authors are accountable for the work.

Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: There are no conflicts of interest to declare.

Employment or Leadership: F.S. Apple, Clinical Chemistry, AACCC.

Consultant or Advisory Role: N.L. Mills has consulted for Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, and LumiraDx. F.S. Apple served on advisory board of Siemens Healthineers and Qorvo Biotechnology.

Stock Ownership: None declared.

Honoraria: N.L. Mills, Siemens Healthineers, Abbott Laboratories

Research Funding: A. Bularga is supported by a Clinical Research Training Fellowships (MR/V007254/1) from the Medical Research Council. N.L. Mills is supported by a Chair Award (GF/F221/00010), Programme Grant (RG/20/10/34966), and a Research Excellent Award (RE/18/5/34216) from the British Heart Foundation. O. Hammarsten is supported by Swedish Heart-Lung Foundation and the Swedish Cancer Society. The University of Edinburgh has received grants from Abbott Diagnostics and Siemens Healthineers (N.L. Mills). F.S. Apple has received research grants (nonsalarised) on cardiac biomarkers through Hennepin Healthcare Research Institute from Abbott Diagnostics, Albott POC, BD, Beckman Coulter, Ortho-Clinical Diagnostics, Roche Diagnostics, Siemens Healthcare.

Expert Testimony: None declared.

Patents: None declared.

References

1. Wong SL, Isserow S, Pudek M. Macrotroponin causing elevation in cardiac troponin I. Can J Cardiol 2014;30:e5–6.
2. Warner JV, Marshall GA. High incidence of macrotroponin I with a high-sensitivity troponin I assay. Clin Chem Lab Med 2016;54:1821–9.
3. Richter W. Determining the subunit structure of phophodies-terases using gel filtration and sucrose density gradient centrifuga-
tion. Methods Mol Biol 2005;307:167–180.
4. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med 2022;28:410–22.
5. Engler RJM, Nelson MR, Collins LC Jr, Spooner C, Hemmann BA, Gibbs BT, et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following small-pox and influenza vaccination. PLoS One 2015;10:e0118283.
6. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Bianes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2636–48.
7. Lam L, Aspin L, Heron RC, Ha L, Kyle C. Discrepancy between cardiac troponin assays due to endogenous antibodies. Clin Chem 2020;66:445–54.
8. du Fay de Lavallaz F, Prepubidis A, Wendebourg MJ, Kesenheimer E, Kyburz D, Daikeler T, et al. Skeletal muscle disorders: a non-cardiac source of cardiac troponin T. Circulation 2022;145:1764–79.
9. Tan SS, Chew KL, Saw S, Jureen R, Sethi S. Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results. J Clin Pathol 2021;74:614.
10. Wang Z, Schmidt F, Wesblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 2021;592:616–22.